Rapid Test Device Properties
The IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device utilizes lateral flow technology that is used for the qualitative, differential detection of both anti-SARS-CoV-2 IgM and IgG antibodies. In general, antibodies can be detected 1-3 weeks after infection. This test is intended to screen patients Combining RNA and Antibody tests can significantly raise the sensitivity of infected individuals.
Likewise, the objective of this test is to evaluate patients. Finally, the combination of RNA and antibody tests can significantly increase the sensitivity of detection in infected individuals.
The product comes in boxes of 25 Tests with one Buffer solution per box.